WCLC 2025 - Posters & ePosters-EP.09.09 Evaluation of Radiotherapy Use in Patients With Metastatic Solid Tumors: An Analysis of Real-World Data

EP.09.09 Evaluation of Radiotherapy Use in Patients With Metastatic Solid Tumors: An Analysis of Real-World Data

Pdf Summary

This retrospective cohort study evaluated the use of stereotactic body radiotherapy (SBRT) in patients with metastatic lung cancer in Brazil from 2019 to 2023. Conducted at Oncologia D’Or, the analysis included 85 patients treated with SBRT, focusing particularly on its application in oligometastatic settings, where limited metastatic disease is present. The intent of the first SBRT treatment varied: 26% was for palliation, 34% for oligoprogression (progression of limited metastases during systemic therapy), 29% for oligometastatic control, and 11% for oligopersistence (stable residual disease).<br /><br />The study found that SBRT contributed to disease control, with 36% of patients achieving complete response, including subsets with EGFR or ALK mutations and those with high PD-L1 expression (≥50%). The median time to change systemic therapy after SBRT was five months, indicating SBRT’s role in maintaining ongoing systemic treatment lines. Median overall survival was 12 months from the first radiotherapy and eight months after the last, reflecting outcomes in a real-world Brazilian population.<br /><br />Despite a limited sample size, this is the first comprehensive Brazilian study describing SBRT use for metastatic lung cancer, particularly in oligometastatic and oligoprogressive disease. The findings underscore SBRT as a valuable modality for local control in diverse clinical scenarios, potentially improving patient management and extending systemic therapy benefits in metastatic lung cancer within a real-world context.

Asset Subtitle

Sofia Mendes

Meta Tag

Speaker Sofia Mendes

Topic Metastatic Non-small Cell Lung Cancer – Local Therapies

Keywords

stereotactic body radiotherapy

SBRT

metastatic lung cancer

oligometastatic disease

oligoprogression

oligopersistence

EGFR mutation

ALK mutation

PD-L1 expression

Brazilian cohort study